SCHEDULE Filed 2025-03-10 Event 2025-03-06 SEC 0001415889-25-007529 →

RA CAPITAL MANAGEMENT, L.P. → Janux Therapeutics, Inc. JANX

Stake: 19.90% Shares: 11,971,377 CUSIP: 47103J105 Class: Common Stock, par value $0.001 per share

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

1 13D/G filings on this issuer

0 other filings besides this one

Filer Track Record

8 filings by this filer

7 other filings in the data moat

Short Interest · settle 2026-03-31

DTC 5.51

7,744,629 shares short · -22.7% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $13.27M

Point72 Asset Mgmt

Other Filings by RA CAPITAL MANAGEMENT, L.P.

Filed	Form	Issuer	Stake	Shares
2025-03-17	SCHEDULE	Mineralys Therapeutics, Inc. MLYS	9.90%	6,287,597	view →
2025-03-03	SCHEDULE	89bio, Inc.	13.70%	20,013,733	view →
2025-02-21	SCHEDULE	Solid Biosciences Inc. SLDB	9.90%	7,989,820	view →
2025-02-03	SCHEDULE	89bio, Inc.	15.10%	20,013,733	view →
2018-03-27	SC	Dicerna Pharmaceuticals Inc	—	—	view →
2018-02-16	SC	Ra Pharmaceuticals, Inc.	—	—	view →
2018-01-19	SC	Dicerna Pharmaceuticals Inc	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. $1,500/mo. Pilots welcome.

Request a pilot →